LG on strategic alliance with Kyorin for urine incontinence drug.

Published: 2005-10-31 06:55:00

Updated: 2005-10-31 06:55:00

LG Life Science signed an agreement of strategic allicance for the market and development of Uritos (imidafenacin), a new therapeutic drug for the incontinence of urine, with Kyorin, a Japanese pharmaceutical company.

LG Life Science has an exclusive distribution right of Uritos in Korea and c...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK